Upon completion of this activity, learners will be able to:
- Explain the guidance from the FDA to industry on development and licensure of vaccines to prevent COVID-19 regarding clinical trials.
- Describe the characteristics of 2 COVID-19 vaccines that submitted a request for an emergency use authorization.